Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities
Authors:
- 10 September 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 29 (2) , 185-198
Abstract
Cancer is considered as one of the biggest threats to human worldwide. Researchers suggest that tumour is not just a single mass, it comprises cancerous cells surrounded by noncancerous cells such as immune cells, adipocytes, and cancer stem cells (CSCs) in the extracellular matrix (ECM) contains distinct components such as proteins, glycoproteins, and enzymes; thus tumour microenvironment (TME) is partially complex. Multiple interactions happen in the dynamic microenvironment (ME) lead to an acidic, hypoxic, and stiff ME that is considered as one of the major contributors to cancer progression and metastasis. Furthermore, TME involves drug resistance mechanisms and affects enhanced permeability and retention (EPR) in tumours. In such a scenario, the first step to accomplish satisfying results is the identification and recognition of this ME, then designing proper drug delivery systems can perform selectively toward cancerous cells. Several targeting and stimuli/enzyme responsive drug delivery systems have been designed. More importantly, it is necessary to design a drug delivery system that can penetrate deeper into the tumours, efficiently, and selectively. Various drug delivery systems such as exosomes and size-switchable nanocarriers (NCs) could decrease side effects and increase tumour treatment results by selective accumulation in tumours. In this review, TME features, current drug delivery approaches, challenges, and promising strategies toward cancer treatment will be discussed.Keywords
This publication has 181 references indexed in Scilit:
- Drug Resistance and Cellular Adaptation to Tumor Acidic pH MicroenvironmentMolecular Pharmaceutics, 2011
- Integrins and bone metastasis: Integrating tumor cell and stromal cell interactionsBone, 2011
- Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumorCancer Chemotherapy and Pharmacology, 2010
- DNA Damage-Mediated Induction of a Chemoresistant NicheCell, 2010
- Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper ChelatorCancer Cell, 2010
- Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)Gynecologic Oncology, 2008
- Stromal fibroblasts in cancer initiation and progressionNature, 2004
- Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinomaBreast Cancer Research and Treatment, 2004
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889